Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 4 studies | 18% ± 3% | |
regulatory T cell | 4 studies | 22% ± 7% | |
monocyte | 3 studies | 25% ± 5% | |
natural killer cell | 3 studies | 17% ± 1% |
Insufficient scRNA-seq data for expression of HERC5 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 708.65 | 651 / 653 | 96% | 10.58 | 578 / 605 |
prostate | 100% | 703.82 | 244 / 245 | 94% | 8.92 | 474 / 502 |
uterus | 100% | 1979.48 | 170 / 170 | 92% | 21.55 | 420 / 459 |
pancreas | 100% | 503.15 | 328 / 328 | 89% | 9.55 | 158 / 178 |
ovary | 100% | 1797.65 | 180 / 180 | 87% | 15.04 | 376 / 430 |
breast | 100% | 848.19 | 458 / 459 | 87% | 13.25 | 975 / 1118 |
kidney | 100% | 653.49 | 89 / 89 | 84% | 7.02 | 759 / 901 |
lung | 100% | 834.72 | 578 / 578 | 83% | 8.64 | 964 / 1155 |
adrenal gland | 100% | 687.47 | 257 / 258 | 80% | 10.26 | 183 / 230 |
esophagus | 93% | 396.68 | 1350 / 1445 | 85% | 10.33 | 155 / 183 |
brain | 84% | 349.77 | 2227 / 2642 | 85% | 11.61 | 598 / 705 |
stomach | 100% | 552.03 | 359 / 359 | 61% | 4.87 | 174 / 286 |
skin | 70% | 234.81 | 1260 / 1809 | 89% | 17.54 | 421 / 472 |
bladder | 100% | 819.67 | 21 / 21 | 58% | 7.65 | 292 / 504 |
liver | 93% | 388.95 | 211 / 226 | 56% | 4.87 | 227 / 406 |
intestine | 100% | 618.01 | 963 / 966 | 41% | 2.97 | 215 / 527 |
spleen | 100% | 1216.45 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 995.09 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 866.85 | 1203 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 22.20 | 44 / 45 |
peripheral blood | 93% | 1744.74 | 862 / 929 | 0% | 0 | 0 / 0 |
heart | 88% | 256.42 | 756 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 76% | 7.03 | 61 / 80 |
lymph node | 0% | 0 | 0 / 0 | 76% | 10.00 | 22 / 29 |
muscle | 44% | 108.90 | 354 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0051607 | Biological process | defense response to virus |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0032020 | Biological process | ISG15-protein conjugation |
GO_0050688 | Biological process | regulation of defense response to virus |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0039585 | Biological process | PKR/eIFalpha signaling |
GO_0045087 | Biological process | innate immune response |
GO_0005829 | Cellular component | cytosol |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0042296 | Molecular function | ISG15 transferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | HERC5 |
Protein name | HECT and RLD domain containing E3 ubiquitin protein ligase 5 E3 ISG15--protein ligase HERC5 (HECT And RLD domain-containing E3 ubiquitin protein ligase 5) E3 ISG15--protein ligase HERC5 (HECT and RLD domain-containing E3 ubiquitin protein ligase 5) E3 ISG15--protein ligase HERC5 E3 ISG15--protein ligase HERC5 (EC 2.3.2.-) (Cyclin-E-binding protein 1) (HECT domain and RCC1-like domain-containing protein 5) |
Synonyms | CEB1 CEBP1 |
Description | FUNCTION: Major E3 ligase for ISG15 conjugation . Acts as a positive regulator of innate antiviral response in cells induced by interferon. Functions as part of the ISGylation machinery that recognizes target proteins in a broad and relatively non-specific manner. Catalyzes ISGylation of IRF3 which results in sustained activation, it attenuates IRF3-PIN1 interaction, which antagonizes IRF3 ubiquitination and degradation, and boosts the antiviral response. Mediates ISGylation of the phosphatase PTEN leading to its degradation, thus alleviating its suppression of the PI3K-AKT signaling pathway and promoting the production of cytokines that facilitate bacterial clearance . Interferes with the function of key viral structural proteins such as ebolavirus structural protein VP40 or HIV-1 protein GAG . Catalyzes ISGylation of influenza A viral NS1 which attenuates virulence; ISGylated NS1 fails to form homodimers and thus to interact with its RNA targets. Catalyzes ISGylation of papillomavirus type 16 L1 protein which results in dominant-negative effect on virus infectivity. Physically associated with polyribosomes, broadly modifies newly synthesized proteins in a cotranslational manner. In an interferon-stimulated cell, newly translated viral proteins are primary targets of ISG15. Promotes parkin/PRKN ubiquitin E3 ligase activity by suppressing the intramolecular interaction that maintains its autoinhibited conformation . .; FUNCTION: (Microbial infection) Functions as an E3 ligase for ISGylation of hepatitis B virus protein X leading to enhanced viral replication due to increased interferon resistance. . |
Accessions | A0A222UC57 A0A222UBP8 A0A222UC18 A0A222UBL1 A0A222UBG1 A0A1B1H4K9 ENST00000264350.8 A0A222UBT1 A0A222UC07 A0A222UBI2 A0A222UBQ9 A0A222UBU1 A0A222UBJ3 Q9UII4 A0A222UBR9 A0A222UBP1 A0A222UBN9 E9PBL0 A0A221SLY6 A0A222UC38 A0A222UBN1 A0A222UBQ7 A0A222UBK9 A0A222UBU5 A0A222UBS8 A0A222UBZ4 A0A222UBP0 ENST00000508159.1 A0A222UBL0 A0A222UBN3 A0A222UBN6 A0A222UBS7 A0A222UC53 A0A222UBK6 A0A222UBP7 A0A222UBQ8 A0A222UBK0 |